Introduction: The extent of early cervical rescreening, defined as rescreening earlier than the recommended interval for a given initial test result, is difficult to determine mainly because the testing history of women is incomplete, especially with newer population based screening registers. Methods: Estimation of early rescreening is based on analysis of a 1 month cohort of women (February 1997) recorded on the New South Wales Pap Test Register (PTR) who initially tested negative and who had no recorded history of a positive test result. For the purposes of estimating early rescreening rates and sources of multiple screening occurring within the recommended 2 yearly screening interval for New South Wales, the cohort excluded the estimated proportion of women with an unrecorded history of a positive result. Approaches to exclusion were different for women with a history of a high grade result (CIN2 or higher) or a low grade result (CIN1 or lower). Results: Characteristic rescreening peaks occurred at 6, 12, 18, 24 and 27 months according to negative result category. The rescreening peak at 27 months illustrates the effect of the PTR late reminder system. After adjusting the cohort for estimated proportions of women with a history of a lesion, the number of women estimated to have rescreened early was ≈156 000 over 1997-8, and the early rescreening rate was estimated as 15.3% of women who have a Pap test. A feasible target for reducing rescreening through service provider interventions was estimated to be a reduction of 7.4%, based on reducing the overscreening proportion from 15.3% to 7.9% through truncating characteristic rescreening peaks to background levels of rescreening. This represents just under 200 000 screens that could be performed over 2 years on New South Wales women who are underscreened or unscreened without incurring additional costs due to screening. Conclusions: Reasonable estimates of early cervical rescreening can be derived but some assumptions in estimating the proportion of women with a positive test result history may be needed particularly if a screening programme is new and universal recording of screening data is only recent. Characteristic peaks, as departures from a background of random noise in time plots of rescreening indicate that a component of early rescreening is systemic and the chief source of such variation in screening behaviour would be service providers.
D espite scant literature, early (short interval) cervical rescreening has been identified as a potentially important problem for Pap screening programmes in Australia . The recommended cervical screening interval in Australia is 2 years, based in part on the findings of the International Agency for Research on Cancer Working Group in Evaluation of Cervical Cancer Screening Programmes. 1 Previous estimates of rescreening in the largest Australian state of New South Wales have been based on assigning all women who screen within 24 months of a previous screen as early rescreeners. Such estimates have been of the order of 40%-45% of all women screened. 2 However, a component of this figure comprises appropriate rescreening in response to screening recommendations based on histories of positive test results, whereas some is unnecessary overscreening according to Australian definitions. This paper attempts to estimate the component of unnecessary overscreening in cervical rescreening.
Possible sources of overscreening have been indicated in several studies. A study of cervical screening in Otago (New Zealand) found short interval rescreening to be most prevalent in younger women (20-29 years). 3 General practitioner (GP) motivations for early rescreening seem to have been influenced by the knowledge that women in younger age groups tend to have higher rates of abnormality. 4 An Australian survey of Pap test results found that 8% of the respondents reported being advised by their GP to rescreen within 3 months of receipt of their negative result because the initial smear sample lacked an endocervical component. 5 In this instance rescreening seemed to be prompted by the perception that a smear sample without an endocervical component is equivalent to an unsatisfactory smear.
As sufficient cervical screening data for New South Wales have accumulated on the New South Wales Pap Test Register (PTR), which started operations in August 1996, it has become possible to examine the issue of rescreening in some detail, especially whether this occurs differentially in response to different categories of negative result.
METHODS

Early rescreening
Early rescreening can be defined as screening before the recommended screening interval for a given type of screening history. Most early rescreening occurs in women with initially negative test results as these women form the vast majority of the screening population. For the purposes of this analysis, early rescreening estimates will be based on a cohort of women with a negative test result who do not have a registry recorded history of abnormality, and who subsequently rescreen before the recommended screening interval. The cohort excluded the estimated proportions of women with a history of a screen detected high grade lesion (histologically confirmed) and of women with a recent history of a low grade lesion (CIN1, human papilloma virus (HPV) effect, atypia) whose previous screening history may not be on the register because of the New South Wales PTR's short operating history. What is of interest are the characteristics of repeat screening in the context of a history of previous exclusively negative test results and a current negative test result. Thus where a sequence of several screens on a person has occurred within the study interval and an abnormal result occurs, then the first instance of this and all subsequent screens are excluded from analysis.
Time cut offs
The first issue to be resolved is an acceptable predefined cut off time which correctly classifies screens occurring early, and those after the cut off as within acceptable limits around the recommended screening interval. This is because women do not rescreen exactly 730.5 days after an initial screen, and may rescreen up to a month or two earlier or later, and still be regarded as screening according to the recommended interval.
An acceptable cut off for early rescreening has been determined as 21 months by the National Advisory Committee for Cervical Screening. Empirically, from New South Wales screening data, this cut off precedes the 23 month point when rescreening in a given cohort dramatically increases. Accordingly, a woman without a history of abnormality who rescreens within 21 months of an initial negative screen may safely be classified as an early rescreener, but a woman who rescreens later than 21 months is not classified as an early rescreener. Similarly, a woman who rescreened within 27 months of her last screen is not classified as an under screener or late screener from these definitions.
Women with a history of histologically confirmed high grade abnormality
The second issue to be resolved is the ascertainment of women with a history of screen detected abnormality (specifically a histologically determined abnormality of CIN2 or worse) where lifetime annual screening is recommended, and where such data are absent. In the case of New South Wales, the PTR has been operational since August 1996, so that women with a history of a high grade abnormality would be incompletely captured on the register. However, estimates of the fraction of women with a high grade result history can be derived by applying a modification to a cross sectional life table method to rates of histologically confirmed high grade lesions found in current screening data. The method relies on estimating the cumulative risk of having such a history in a hypothetical cohort-that is, the risk cumulated by a given age of having a past, histologically confirmed, screen detected high grade lesion. Thus, a cumulative rate 6 is defined as: cumRate=∑n i ×r i , where n i =number of years in age bracket i, r i is the event rate for age group i and: a cumulative risk=1−exp(−cumRate). The past cumulative risk estimated for each age group is that accruing up to the given age group and represents the estimated prevalence in each age group of women with a history of a histologically confirmed high grade lesion. The overall prevalence is then a weighted sum of the age specific past cumulative risks, weighted according to population proportions in each age group. The overall historical rate is taken as this prevalence. This then becomes the basis for discounting for the proportion of women with negative test results who have a history of a high grade lesion.
Further adjustment of the high grade historical rate estimate is required to take into account the fraction of women with a high grade result who subsequently had a hysterectomy and therefore no longer have a cervical screen; and of the increased risk in women with a pre-existing high grade lesion of having a subsequent high grade result, and who therefore contribute to an overestimate of the proportion with a history of a high grade lesion. Such adjustment would logically involve first discounting the hysterectomy fraction, then discounting the estimated proportion of women remaining who have subsequent high grade test results, as this group can only comprise women with an intact cervix.
Estimation of the hysterectomy fraction in women with a history of a high grade test result is based on findings from a study of cone biopsies for completeness of excision. 7 This proportion was found to be 18% and is a first approximation of the women who subsequently would have undergone a hysterectomy as a result of conisation failing to completely excise the lesion. This hysterectomy proportion, based on the only evidence available, is probably an overestimate of the true proportion as partial excision can also be completed by another conisation rather than a hysterectomy. Additional numbers of women from the cohort whose excision was complete, but who underwent hysterectomy for other reasons, brought the total proportion to 24%. This proportion is then taken as the estimate of the future hysterectomy fraction in a group of women who have a history of a high grade test result.
In most women with a hysterectomy who have a subsequent Pap smear the smear is a vault smear and is not sent to the PTR, so these smears are not included in the analysis. Accordingly, the full estimated hysterectomy fraction is then applied to exclude the estimated proportion of women with a history of high grade test results before further exclusions.
Data used to calculate the adjustment for women with a history of a high grade lesion who subsequently test more often with positive results come from Mitchell et al 8 in which proportions of women with initially high grade results whose subsequent test results indicated recurrent abnormalities were estimated. This screening proportion was also estimated to be 24%, and was based on a weighted mean of the proportions found in the different high grade result categories.
In New South Wales the estimated proportion of women screened with a history of a high grade lesion (confirmed by histology) was 15%-17% (according to year examined). For the purposes of discounting the early rescreening estimates, 16% was adopted as the initial estimate of women with a history of a high grade abnormality. The 16% of women was then discounted first for the estimated hysterectomy fraction of 24%, bringing the fraction to 12.2%. This proportion is then discounted by a further 24% to account for the higher recurrence of positive results in these women. The final estimate of women with a high grade test result who should be discounted from crude early rescreening estimates is then 9.2%. This proportion applies to all women tested, and may not be the same as that in a cohort of women whose test result is initially negative. However, this information is all that is available.
Women with a history of low grade lesions who test more often than every 2 years A more complicated situation exists for the unknown proportion of women with a history of a low grade lesion. For those with a test result of non-specific minor squamous cell changes or atypia, the recommended screening interval is 12 months until reversion to normal. Most of these abnormal results are not confirmed by histology. With histologically confirmed HPV effect or CIN1, or both, the recommended screening interval is every 6 months until two successive negative results occur, thereafter the recommended screening interval is annual for 2 years, then the screening interval reverts to every 2 years if the annual results are normal. In any given 2 year period a proportion of women with an initially negative Pap test result will have had a history of low grade lesions that are not recorded in the registry screening data. This is exacerbated in the case of the New South Wales PTR, where a considerable proportion of women in the index month chosen for this analysis (February 1997) who tested negatively may have had a low grade lesion on their previous Pap test but are not on the New South Wales PTR before the index month. This unknown proportion of women must be estimated to further discount the estimated rates of early rescreening. The approach used previously for estimating the unknown proportion of women with a high grade lesion cannot easily be applied to estimate this proportion as not only is the recommended screening interval not lifelong after such a result, but varies according to subsequent test results occurring at the various recommended screening intervals (6 or 12 months as the case may be).
The following simple approach was taken. An index cohort with negative cytology results for February 2000 was extracted and retrospectively examined to estimate the proportion of these women who had a low grade lesion in the previous 27 months. This proportion would then be an estimate of the unknown proportion in the February 1997 index cohort of women with a negative test result who have an unrecorded recent history of a low grade lesion. The estimated proportion of women in the cohort with a recent history of CIN1 with or without histologically determined HPV was based on examination of cytologically determined rates of CIN1 with or without HPV from known comparisons of cytological versus histological result classifications.
The estimated proportion of women with a recent history of atypia or mild inflammation was 5.24%. The estimated proportion of women with a recent history of CIN1 with or without histologically determined HPV was 0.51%. The total estimated proportion of women with a negative test who had a recent test result of a low grade lesion is therefore 5.75%.
Index cohort sample
The procedure for estimating the extent of early rescreening begins with the creation of an index cohort of women selected from a month that is seasonally neutral for screening. The month chosen for this analysis was February 1997. The index cohort then consisted of all women whose Pap test was initially negative in the index month and who have no registry recorded history of a positive test result. The index cohort was then divided into the six possible test negative categories as defined in table 1. This was to examine whether results depended on systematic patterns in early rescreening. Time plots to the first rescreen of each category of women with negative results were then produced to ascertain any time related patterns in retesting by the index negative result category. Similar plots were produced of cumulated repeat testing where those who tested once only within 27 months, twice only, three times only, and four times only were plotted together. Empirically, the highest proportions of negative screen results occur in three of the negative result categories in table 1: endocervical component present, inflamation absent (1), endocervical component present with squamous cell inflammation (2) , and endocervical component absent without inflammation (5) . The screening data also showed that the numbers of women repeat testing more than four times in the 27 month period were very small and could be ignored. The rescreening categories then were of women who had one, two, three, or four repeat Pap tests in the period after the index month, broken down by negative result category for further analysis.
For a woman to be classed as screening early after the index month, the first retest result must be negative. If the test result after the index result was positive then this and all subsequent tests were not classified as early rescreens.
Estimating the extent of early (short interval) cervical screening Total counts of women who fall into the various rescreening categories were computed and multiplied by 24 to cover the 2 year screening interval and provide a biennial estimate of early rescreening. As the index sample comprised a seasonally neutral month of screens, multiplication of this estimate by 24 is adequate. The final estimate was derived after discounting the computed early rescreening number by 9.2% to allow for the estimated fraction of women with a history of a histologically confirmed high grade abnormality; and by 5.75% to allow for the estimated fraction of women with a recent history of a low grade abnormality. The total proportion wxcluded was therefore 14.95%.
Criteria for estimating targets for efficacious reduction of early rescreening of the cervix The basis for estimating targets of screens for reducing early rescreening relies on distinguishing in time plots of rescreeners particular periods which seem to be a systematic phenomenon above and beyond a background of randomly occurring rescreening activity. For example, when screening behaviour is plotted for a cohort who initially tested negative, characteristic peaks of rescreening activity appear at 6, 12, and 24 months after the index screen (fig 1 A, B , and 1 C). Because these peaks are clearly distinguishable from the background of rescreening activity in the time plots they must be the result of a systemic influence, either a policy or service provider, on the screening behaviour of the population. Conversely, if the peaks were to originate in the women themselves then why does womens' rescreening activity aggregate around the 3, 6, and 12 month intervals? Furthermore, the numbers of screens that occurred in plots of multiple rescreening activity could be estimated, particularly under the characteristic peaks, and were appropriately adjusted for the unknown proportions of women with histories of abnormalities. These would then serve as targets for efficacious reduction by interventions among the service providers.
In this paper, targets for reducing rescreening are expressed in numbers of tests rather than patients as the numbers of tests give an indication of the number of unscreened or underscreened women who potentially can be recruited to screening at a cost in terms of testing, but not necessarily recruitment, which is neutral.
As table 1 shows, it is conceivable that a GP or laboratory may recommend that a woman rescreen earlier than the screening interval if, for instance, there was some inflammation and no endocervical component present (variants 5 and Figure 1 A shows the number of women from the cohort who had a repeat test by time in months to the first repeat Pap test during the next 43 months. Distinct peaks occured at 6, 12, and 24 month intervals, and just after the 27 month interval, coinciding with the various National Health Medical Research Council (NHMRC) recommended test intervals for initially non-negative test results (6 and 12 months), the recommended screening interval for initially negative test results (24 months), and GP or the PTR late reminder interval (27 months). The largest peak at 12 months suggests most of the overscreening is concentrated at this interval.
The largest negative result category, where there is no inflammation and where an endocervical component is present, accounted for about 82% of all negative test results, and consequently plots of this category are almost identical to the time plot for all women who initially tested negative (fig 1  A and B) . Figure 1 C shows the second most common negative result, comprising about 13% of negative test results, where no squamous cell inflammation was detected and no endocervical component was present. The largest repeat screening peak occurred at 3-6 months, followed by a peak at 12 months, with smaller peaks at 24 and 27 months. The 3-6 month peak is most probably due to recommendations for a patient to rescreen due to lack of the endocervical cells being equated to an unsatisfactory smear. The third most common negative test result category, where squamous cell inflammation was detected and an endocervical component was present, comprised about 4% of all negative test results, is shown in figure 1 D. Despite the low numbers, distinct peaks appeared at 6 months and at 12-15 months. The three most common categories of negative test result accounted for 99% of all negative results.
All the time plots of first repeat cervical rescreening (fig 1  A-D) have a rescreening peak just after 27 months which illustrates the effect of the 27 month late reminder system of the PTR which results in a screening peak within the next month.
In figure 2 A, a plot of multiple rescreening activity for those in the cohort whose index negative test detected no inflammation and where an endocervical component was present in the smear, repeat screening peaks occur at 12, 15, 24, and 27 months. Figure 2 B shows of women whose index negative test result detected no squamous cell inflammation and contained no endocervical component in the smear. These show multiple rescreening peaks at 3 and 12 months as well as the 24 and 27 month peaks. Figure 2 C is a plot of multiple rescreening activity of the cohort where the index negative test result detected some squamous cell inflammation with an endocervical component present in the cytological sample. Characteristic screening peaks in this group occurred at 6, 12, and 21 months after the index test. In plots 2 A-C, lines drawn beneath the characteristic multiple rescreening peaks indicate the basis for estimating attainable targets for reduction of rescreening.
Estimates of the total number of women rescreened early in a 2 year period and as a percentage of all women screened, with feasible target numbers of screens based on the characteristic screening peaks, are shown in tables 2 and 3, after classifying rescreening by the number of repeat screens. For target calculations each of the 12 month peaks was adjusted by the full 14.95% for the unknown proportion of women with high and low grade screen detected lesions, as these peaks also include women who may be screening legitimately every 6 months. The peaks occurring at 6 months were adjusted by 9.71% (made up of the high grade history exclusion factor of 9.2% plus the exclusion of the estimated proportion in the cohort of those with a recent history of CIN1 or HPV (0.51%), and who would be recommended to have 6 monthly tests if observational follow up for such a test result was chosen).
From table 2, the highest prevalence of a negative result where early retesting occurred was in the "ideal" negative From table 3 , the estimated total (biennial) of inappropriate early screens was 395 880 for 1997-8. The corresponding feasible target (biennial) for reduction was estimated as 199 032 tests. The corresponding number of women who screened early (biennial) for 1997-8 was estimated as 156 493. The corresponding feasible target of women for reduced screening (biennial) was estimated as 75 776 women. Overall, it would seem that test based or woman based early rescreening targets for possible reduction are about half the total number of early rescreens.
From table 3 , the estimated early rescreening rate for New South Wales for 1997-8, based on a total of 1 021 413 New South Wales women who screened over the period, was 15.3%. The feasible target for reduction of the early rescreening rate would then be 7.9%. That is, a feasible target for reduction of rescreening in New South Wales is from 15.3% to 7.9%, based on eliminating 7.4% of screening contained in the screening peaks. If about 76 000 over screened women were appropriately screened this would result in about 199 000 unscreened women who could be screened without additional cost due to screening.
DISCUSSION
Early cervical rescreening is difficult to define and estimate. In New South Wales estimates of rescreening rates have tended to be of the order of 40%-45% of all women who screen, when all repeat tests occurring within 24 months of an initial test are counted. 2 These estimates have been based simply on intervals between screens without accounting for earlier screening history or test results. Such rescreening rates are poor estimates of rates of inappropriate early rescreening and give no indication as to how early rescreening might be reduced, let alone the targeting of such endeavours.
The main obstacles to estimating and adjusting for the proportions of women with past screen detected abnormalities centre on laboratory reporting requirements to the New South Wales PTR, compounded by the recent start (August 1996) of the organised cervical screening programme in New South Wales. By law, before August 1996, laboratories were not required to report to the PTR cytological screening or histology results, nor were they required to flag women with such histories. Consequently this information was not collected, although discussions are in progress to record the histories voluntarily provided by smear takers and women. Only as test results accumulate over time on the PTR will improved estimates of prevalences of past abnormality be gained. This is especially the case with estimating the prevalence of women in the cohort with histories of low grade lesions (<CIN1), where for the present investigation these were estimated from a later PTR cohort. A replication of the present study in 2 or 3 years time would be able to estimate directly in a cohort the historical rate of low grade lesions from sufficient past test results accumulated on the PTR.
In estimating the proportion of women with an unknown history of a high grade lesion it was assumed that all these women would rescreen according to the national guidelines for follow up of cervical abnormalities. This assumption may not be adequate but can only be tested as further screening data accumulates on the PTR. However, this assumption would tend to overestimate the number of women legitimately rescreening before the recommended screening interval of 2 years and therefore would produce a conservative estimate of the extent of inappropriate early rescreening.
Some of the screening peaks in the time plots of repeat screening activity coincide with recommended screening intervals and the operation of cervical screening reminder systems. The 27 month peak is most probably due to a combination of GP and self reminders at 24 months and the 27 month back up reminder system administered by the New South Wales PTR. The 3, 6, and 12 month screening peaks in the three most prevalent grades of initially negative results examined here represent over screening resulting from systemic influences. The most probable influence would be service provider initiatives, as this study confirms in particular the survey of Schofield et al 5 where a considerable proportion of the respondents (8%) reported being advised by their GP to rescreen within 3 months of receipt of their negative result because the initial smear sample lacked an endocervical component.
In general, patients tend to follow the recommendation of their GP. The GPs in turn may follow laboratory recommendations on test results. These may or may not comply with NHMRC management recommendations. From a medicolegal standpoint, a proportion of GPs may feel obliged to follow a laboratory recommendation regardless of its compliance with NHMRC screening guidelines. Importantly, the cytology laboratory may know that a woman has a history of a screen detected abnormality whereas the GP or PTR may not. However, there was no provision on the PTR for history to be reported, nor was there a requirement to report Pap tests to the PTR before 1996. Accordingly, many GPs may screen their patients more often than NHMRC recommendations as a precautionary measure. It is also possible that some GPs may recommend that unscreened or underscreened patients rescreen early when no endocervical component has been collected in the smear sample or if some inflammation was detected. It follows that it would be particularly suitable to target service providers to conform to screening guidelines, and that targets to reduce early repeat screening would be feasibile with this approach.
From the estimates of reduction in test numbers from early rescreening it would seem that in New South Wales potentially about 400 000 unscreened women per 2 years could be recruited to screening in a manner that would produce no new tests-if early rescreening is reduced to zero, which may not be achievable. Efficacious reductions in early rescreening, by targeting service providers, are estimated to be about 200 000 screens over a 2 year cycle, or about one half the total number of early rescreens. This estimate is based on reducing the characteristic multiple rescreening peaks (fig 2 A-C) to levels similar to the background of rescreening activity. These estimates assume the screening peaks to be the result of influences from the service provider on screening behaviours in the absence of viable alternative explanations. If this is the case it may be possible to reduce the peaks to below the background level as targeting service providers would potentially affect all rescreening at the characteristic peaks. Also, it is probable that the factors used to adjust rescreening activity due to unknown test histories are an overestimate of the true fraction of positive test results. Therefore the estimates of overscreening and the targets for reduction are on the conservative side. Accordingly, strategies directed at GPs and cytology laboratories would be the most efficacious in reducing inappropriate early rescreening in New South Wales.
